Share

Community Service: How Joshua J. Joseph, MD, MPH, Is Leveling the Healthcare Playing Field for All

GO_HRTUXYAAqdQR When his grandmother succumbed to a heart attack when he was only eight years old, Joshua J. Joseph, MD, MPH, was determined to end as much suffering as he could. The recipient of the Endocrine Society’s 2024 Richard E. Weitzman Outstanding Early Career Investigator Award, he details his ongoing endeavors to make sure Black Americans...
Share

Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs to Be Presented at ENDO 2024

Five abstracts from Crinetics Pharmaceuticals’s clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston – including initial data from a Phase 2 Trial of atumelnant in congenital adrenal hyperplasia (CAH). “This year’s Endocrine Society meeting represents a major milestone for...
Share

Baseline Data from the CAHtalyst™ Program in CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Presented at ECE 2024

Neurocrine Biosciences, Inc. and Diurnal Ltd., a Neurocrine Biosciences company, in May presented baseline data from the CAHtalyst™ Phase 3 studies of crinecerfont in adult and pediatric patients with congenital adrenal hyperplasia (CAH), and modified-release hydrocortisone (Chronocort®) data for a Phase 2 clinical study (CHAMPAIN) in participants with primary adrenal insufficiency and in a Phase 3 extension study in...